Heffernan Michael Thomas 4

What Happened

• Michael Thomas Heffernan, a director of Trevi Therapeutics (TRVI), was granted an option on June 3, 2026 to acquire 35,000 shares. The transaction is reported as a derivative award with an acquisition amount of $0 on the Form 4 — this is a grant of options, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Instrument: Option grant (derivative) to acquire 35,000 shares; reported acquisition amount $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, subject to continued service as a director, employee or consultant.
• No indication of immediate sale or cashless exercise in this filing.

Context

• This is an option grant (compensation/retention award) to a director. Such awards are common for directors and reflect compensation rather than a direct buy/sell signal; they do not necessarily indicate the insider is buying shares on the open market.